All News
Check SSc-ILD Patients on Nintedinib for Malnutrition
During nintedanib treatment for interstitial lung disease associated with systemic sclerosis (SSc-ILD), clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested.
Read Article
FDA Delays Bimekizumab Decision, Again
Editor's Note: please note the error in the original report has been corrected to read: UCB affirms there are no open information requests from the FDA regarding the BLA for bimekizumab or bimekizumab manufacturing.
Read Article
Paradoxical Psoriasis in Kids Taking TNF Inhibitors
A multicenter cohort study reported a large cohort of pediatric patients receiving TNF inhibitor therapy complicated by psoriasis, regardless of treatment indication or the specific TNF inhibitor.
Read Article
TitAIN Study: Secukinumab Efficacy in Giant Cell Arteritis
A phase 2 trial has demonstrated the efficacy of secukinumab, an anti-interleukin-17A monoclonal antibody, in patients with active giant cell arteritis (GCA).
Read Article
Are bDMARDs, tsDMARDs and biosimilar DMARDs cost effective?
Treatment advances with new biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) have proven efficacy and safety; but does their increased cost yield commensurate benefits in patients with rheumatoid arthritis (RA) and high disease activity?
Read Article
Abatacept Safety Outcomes Across 7 European Registries
A multinational registry analysis of rheumatoid arthritis (RA) receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.
Read Article
How Often Do You Monitor MTX? (6.16.2023)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com, including new drug approval, a new SpA variant and new rules for methotrexate (MTX) monitoring and depression screening.
Read Article
Biosimilars Match Biologic Originators in Rheumatoid Arthritis
A systematic review and meta-analysis in JAMA Network Open has shown that biosimilars of adalimumab, infliximab, and etanercept were associated with clinically equivalent treatment effects compared with their reference biologics for the treatment of rheumatoid arthritis (RA).
Read Article
EULAR 2023 Notes from Milan (6.09.2023)
Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy.
Read Article
EULAR 2023 – Day 3 Report
Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.
Read Article
EULAR 2023 – Day 2 Report
Day 2 at the international EULAR Congress meeting is always bigger and busier. There were sessions on JIA therapies, crystal arthritis, novel drugs for SLE and Sjogren's, early RA and preclinical RA interventions, IgG4 disease, osteoporosis and the growth and application of artificial intelligence in medicine and rheumatology.
Read Article
EULAR 2023: Featured Industry Presentations
EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR
Read Article
Belimumab in Lupus Nephritis
Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor that is FDA approved for the treatment of active lupus and lupus nephritis, based on a few pivotal trials; and now a metanalysis supports its use in active lupus nephritis.
Read Article
3-4-5 Rule (5.26.2023)
Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.
Read Article
Prevalence of Psoriatic Arthritis, Spondyloarthritis and Rheumatoid Arthritis in Norway
Recent reports have suggested a rising and unrecognized number of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) compared to rheumatoid arthritis (RA).
Read Article
Falls with Knee Osteoarthritis
A study of adults aged 45-85 yrs shows that knee osteoarthritis (OA) is an independent risk factor for falls, suggesting a greater need for awareness and prevention.
Read Article
NSAID Prescribing Decreasing
Multinational metanalyses of data between 1989 and 2022 shows that NSAID prescriptions have decreased over time, and differs according to geographical locations.
Read Article
How Age of Onset Affects Giant Cell Arteritis
Giant cell arteritis (GCA) has a different phenotype when diagnosed late in life compared with earlier onset, a large Italian cohort study indicated.
Read Article
